Latest update: September 15th, 2013
This year marks the 80th anniversary of the influential paper published by a Mount Sinai physician, Dr. Burrill Crohn, and his colleagues that for the first time characterized a disease associated with severe inflammation of the intestine. Patients with what was later named Crohn’s disease develop diarrhea, fever, stomach pain, and often lose weight. Crohn’s is now classified as an autoimmune condition in which the immune system attacks its own healthy tissue in the gastrointestinal tract, causing chronic inflammation. It affects young individuals, and, even though it is not curable, it can be treated and controlled by medications and surgery.
Epidemiology and origination of Crohn’s Disease
Crohn’s is considered to be a complex disease with both genetic and environmental risk factors. There is extensive evidence to support the role of genetics in the development of Crohn’s disease. Having a relative with Crohn’s disease is the greatest risk factor for other family members. Also, studies of twins have shown that identical twins, who share almost 100% of their genetic information, were more likely to both have the disease than fraternal twins. The differences in the prevalence of Crohn’s in various racial and ethnic groups further indicate that genetic factors contribute to the risk, even though shared cultural factors, such as diet and lifestyle, might also explain these differences. Specifically, the prevalence of Crohn’s disease in European countries ranges between 1 and 12 per 100,000 individuals, whereas this disease was until recently virtually unknown in the developing countries.
The major genetic risk for Crohn’s disease identified so far is conferred by 3 rare mutations in the NOD2 gene. NOD2 plays an important role in the immune system, as it enables immune cells to recognize bacterial molecules and stimulates an immune reaction. While the frequency of these mutations ranges between 1% and 4.5% in the general population, about 40% of Crohn’s disease patients carry at least one copy. This translates to a 2 to 4-fold risk of developing the disease in carriers of one copy and a 10 to 40-fold risk in those who carry multiple copies of these mutations. Recent advances in the field of genetics have allowed identification of an additional 160 genetic variants associated with Crohn’s disease in individuals of European ancestry. However, a sharp increase in the occurrence of the disease in children of immigrants from the developing countries who move to Western countries, as well as the well- established effect of smoking on Crohn’s disease risk, suggest a prominent role for environmental factors as well, most likely diet and lifestyle.
Crohn’s Disease in the Ashkenazi Jewish Population
Interestingly, Jews of European descent (Ashkenazim) have a 4 to 7-fold increased risk of developing Crohn’s disease compared to non-Jewish Europeans. Genetic risks alone could not explain why the prevalence of Crohn’s disease is so much higher in Ashkenazim than in surrounding populations. To investigate this phenomenon, researchers from the Mount Sinai School of Medicine have recently conducted the largest study which compared 1,878 Ashkenazi Jews with Crohn’s disease to 4,469 Jews without the disease, using DNA samples to evaluate their genetic make-up. They discovered five new genetic risk regions associated with Crohn’s disease in Ashkenazim. Armed with this new information, they can begin to pinpoint additional causal genetic mutations, discover the nature of the malfunctions they create, and hopefully eventually develop new treatment approaches. That study also demonstrates the value of genetic studies in isolated populations, like Ashkenazi Jews.
The Role of Commensal Bacteria in Crohn’s Disease Risk
One possible explanation for the origination of Crohn’s disease is the hygiene hypothesis which suggests that a lack of early childhood exposure to infectious agents causes the immune system to wrongfully recognize its own non-pathogenic microorganisms as imminent risks and to act against them, causing substantial damage. This notion is particularly interesting in light of accumulating evidence suggesting that the identity and relative abundance of members of bacterial communities, or microbiota, normally residing in the human body and referred to as “commensal”, or non-harmful, bacteria, can be associated with different disease states. Microbial cells that live on (skin, eyes) and inside the human body (digestive system) may outnumber the quantity of human cells by 10-fold. This means that we may be carrying more bacterial genes than our own. Some commensal bacteria are essential for our health and provide a wide range of metabolic functions that the human body lacks. They help break down, absorb and store nutrients that otherwise cannot be digested, fight pathogenic bacteria, and play an important role in the development of the immune system.
While we know that exposure to pathogenic organisms can cause disease (e.g., stomach flu), little is known about whether there is a common core set of microbes (microbiome profile) that is shared between healthy people or individuals with the same disease. We already know that changes in diet, antibiotic treatment and various conditions, including obesity, may shift our normal bacterial balance. Small studies have shown a lower diversity of the gut microbiota found in Crohn’s disease patients compared to unaffected individuals, raising questions about the possible role of commensal bacteria in disease development. Moreover, the fact that the major genes found to be associated with Crohn’s disease are involved in the processing of microbial antigens and immune response further implicate commensal bacteria in the Crohn’s disease risk.
Despite preliminary data indicating substantial differences in gut microbial content between healthy individuals of different racial and ethnic backgrounds, no studies have compared a composition of the bacteria between Ashkenazim and non-Jewish Europeans. It should not be surprising if such differences exist, given the unique dietary and lifestyle traditions observed by Jews including kosher food and a mandatory hand-washing before meals (“netilat yadaim”) that could reduce exposure to infection. Therefore, under- or overrepresented microbiota in this population may help guide future efforts in developing novel treatments targeting commensal bacteria.
The use of isolated populations in genetic research has been demonstrated to be of special value by revealing how small inter-individual differences in their human genome sequence increase the chances of detecting mutations that are disease-associated. Therefore, to help advance our understanding of complex diseases, the Ashkenazi Genomic Consortium was established. The “Ashkenome” is a new collaborative initiative seeking to identify how the unique genetic make-up of this population contributes to various conditions, including diabetes, Parkinson’s disease, schizophrenia, or aging. This information, along with microbiome data, can be used in future studies of more diverse populations and help lead to early diagnosis, a better means of prevention, and novel treatments for complex diseases such as Crohn’s.
Inga Peter is the Associate Professor in the Department of Genetic and Genomic Sciences at the Mount Sinai School of Medicine. Her research interest is to identify variations in the human genome that can explain susceptibility to common diseases such as obesity, diabetes, and Crohn’s disease that can lead to early prevention and personalized treatment of these conditions. She graduated from Tel Aviv University and completed her training at Tufts University in Boston. She lives in Westchester County, NY with her husband and 3 sons.Dr. Inga Peters
About the Author: Inga Peter is the Associate Professor in the Department of Genetic and Genomic Sciences at the Mount Sinai School of Medicine. Her research interest is to identify variations in the human genome that can explain susceptibility to common diseases such as obesity, diabetes, and Crohn’s disease that can lead to early prevention and personalized treatment of these conditions. She graduated from Tel Aviv University and completed her training at Tufts University in Boston. She lives in Westchester County, NY with her husband and 3 sons.
If you don't see your comment after publishing it, refresh the page.